A new RAND report shows nearly 12% of U.S. adults now use GLP-1 drugs like Ozempic and Wegovy, and it’s changing how they shop. Food companies say the biggest shift isn’t in portion sizes but in the ...
By Danny Barrett, Jr. University of Mississippi Medical Center JACKSON – Drugs initially approved for diabetes are now an ...
The Brighterside of News on MSN
GLP-1 drugs like Ozempic and Wegovy are changing the foods Americans buy
The impact of popular U. S. weight-loss drugs like Ozempic and Wegovy (GLP-1 receptor agonists), upon their initial ...
Flow Space on MSN
What we learned this year about midlife GLP-1 use
A growing body of research and experts have suggested that GLP-1s can be powerful tools for midlife women. Here’s what we ...
GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity or overweight with a related health condition. Read on for everything you need to know about GLP-1s for weight loss, ...
Brooke Boyarsky Pratt, CEO, and Dr. Angela Fitch, chief medical officer, are both co-founders of knownwell. More than 12% of U.S. adults now take a GLP-1 medication, marking one of the ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide and liraglutide mimic endogenous incretin signals to stimulate glucose-dependent insulin release, thereby suppressing glucagon, ...
Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average of nearly 8% of their body weight after 40 weeks and ...
The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety ...
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...
MedPage Today on MSN
GLP-1 agents showed broader risks, rewards in 2025
While the FDA has yet to issue a warning for NAION, it is actively monitoring reports of the condition linked to GLP-1 drugs.
GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence suggests.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results